Chemours Co (CC): Nasdaq/NYSE listing notice — Chemours receives NYSE noncompliance notice for delayed 10-K filing

Chemours Co

NYSE notified Chemours on March 18, 2024 that it is not in compliance with Section 802.01E for failure to timely file its 2023 Form 10-K.
Company has six months from March 15, 2024 to file the 10-K and regain compliance with NYSE listing standards.
Delay due to additional time needed for year-end reporting process and review of internal control over financial reporting as of Dec 31, 2023.
Previously disclosed internal review by Audit Committee has been substantially completed.
Chemours expects to file the 10-K as promptly as practicable and will schedule Q4/full-year 2023 earnings call separately.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Chemours Co received a nyse noncompliance notice notice regarding late filing (rules 802.01E).

Exchange: nyse
Notice: noncompliance notice
Deficiency: late filing
Rules: 802.01E

Exact text from the filing

March 18, 2024, the New York Stock Exchange (the “NYSE”) notified The Chemours Company (the “Company”) that it is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2023 (the “Form 10-K”). In accordance with the NYSE Listed Company Manual, the Company has contacted the NYSE to discuss the status of its Form 10-K filing. On March 18, 2024, the Company issued a press release with respect to the receipt of the notice of noncompliance from the NYSE. A copy of the press rel

View on SEC.gov

Browse all listing & compliance notices →

Chemours Co filing history →

Source: SEC EDGAR

accession 0001193125-24-070332

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.